POWERED BY

NEWS

Lexology Webinar
February 22, 2018

 

Inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the USPTO have been popular since their inception in 2012, and petitions are increasingly being filed against biologic drug patents.  Fitzpatrick Cella’s award-winning intellectual property attorneys provide you with unique insights and the latest statistics on biologic drug IPRs and the lessons to be learned from recent institution and final written decisions.

Corinne Atton, Whitney Meier, and Robert Schwartz will discuss:

  • Statistics related to CDER-listed (“Purple Book”) biologic drug IPRs including: IPR petitions filed, patents challenged in both IPR and district court litigation, claim types challenged in IPR, IPR outcomes, and comparisons to data on IPRs filed against Orange Book listed patents.
  • Lessons learned from analyzing biologic drug IPRs by claim type: methods of treatment, formulation, composition of matter, and process/manufacturing.

This webinar is perfect for life sciences professionals interested in understanding how IPRs are being used to challenge biologic drug patents.

Join us on Thursday, February 22, 2018 at noon EST for this complimentary webinar.

 


METHODOLOGY

Information contained in the Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics Graphics are compiled from information contained in the Fitzpatrick BiologicsHQ database.

DISCLAIMER

BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for business. Links or references to third party sites or resources are provided for informational purposes only.

SUBSCRIBE FOR FUTURE UPDATES

captcha